Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5821758 | Antiviral Research | 2016 | 7 Pages |
Abstract
Dengue virus (DENV) infectious disease is a major public health problem worldwide; however, licensed vaccines or specific antiviral drugs against this infection are not available. To identify novel anti-DENV compounds, we screened 1280 pharmacologically active compounds using focus reduction assay. Bromocriptine (BRC) was found to have potent anti-DENV activity and low cytotoxicity (half maximal effective concentration [EC50], 0.8-1.6 μM; and half maximal cytotoxicity concentration [CC50], 53.6 μM). Time-of-drug-addition and time-of-drug-elimination assays suggested that BRC inhibits translation and/or replication steps in the DENV life cycle. A subgenomic replicon system was used to verify that BRC restricts RNA replication step. Furthermore, a single amino acid substitution (N374H) was detected in the NS3 protein that conferred resistance to BRC. In summary, BRC was found to be a novel DENV inhibitor and a potential candidate for the treatment of DENV infectious disease.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Fumihiro Kato, Yuki Ishida, Shinya Oishi, Nobutaka Fujii, Satoru Watanabe, Subhash G. Vasudevan, Shigeru Tajima, Tomohiko Takasaki, Youichi Suzuki, Koji Ichiyama, Naoki Yamamoto, Kentaro Yoshii, Ikuo Takashima, Takeshi Kobayashi, Tomoyuki Miura,